Jazz Pharmaceuticals appoints vice president of r&d

Jeffrey Tobias also takes chief medical officer role

Jazz Pharmaceuticals, a US developer of pharmaceuticals for neurology and psychiatry based in Palo Alto, California, has appointed Jeffrey Tobias, as senior vice president of research and development and chief medical officer. He takes up his new roles on 17 October.

Tobias has 20 years of experience in the biopharmaceutical industry across all phases of drug development, including regulatory filings in the US and Europe.

He has broad experience with a variety of therapeutic products spanning numerous clinical areas, including pain and neurological disorders.

Most recently, he was executive vice president of research and development at NeurogesX, where he has also been chief medical officer since 2005.

Prior to this Tobias was managing director of an independent biopharmaceutical consulting firm from 1996 to 2006, where he supported clients in all aspects of clinical development, technology assessment and strategic planning. He has also served in various roles in drug discovery and clinical development at ALZA, Chiron and XOMA.

Tobias also has 10 years of experience in clinical and academic medicine, focusing on internal and pulmonary and critical care medicine.

You may also like

Pharmaceutical

Jazz Pharmaceuticals commercialises enhanced antibody, Ziihera, for biliary tract cancer

The therapeutic antibody was developed using ProBioGen's GlyMaxX technology, creating an afucosylated product with more ADCC-mediated cell killing activity
Design & Build

Jazz Pharmaceuticals among ISPE FOYA winners

Ardmac supplied and installed the cleanroom in the biopharmaceutical company's winning facility in Ireland
Finance

Jazz concludes merger with Azur Pharma

Forms a specialist in CNS and women’s health products
Manufacturing

Anxine responds to rising demand for integrated turnkey packaging solutions

Anxine has observed that more customers are moving away from purchasing individual machines and are instead choosing complete one-stop turnkey solutions that are easier to plan, manage, and put into operation
Pharmaceutical

MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients

The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
Regulatory

How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing

As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Subscribe now